Page 2 - Immunogenicity Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Months after the primary series and all we have are what are called serologic data, antibody data, measured four weeks and six weeks after the booster. we don't have effectiveness. these are just the immunogenicity data. i can imagine the fda will have their hands full in the next day and a half to really get their brains around all of this. i'm still in the middle of getting through it all. it's pretty complicated. >> i bet, it is. and listen, this just came out this afternoon. it is developing as we speak. can you put this, though, dr. azar, as you do so well, like if you got a vaccine other...

Jake? >> yeah, they've been criticized, in fact, the biden administration for putting pressure on the fda. elizabeth cohen, thank you so much. i want to bring in a professor at vanderbilt medical center who studies infectious disease and preventive medicine. dr. schaffner, what do you make of this first vote by the fda panel against recommending a third dose or a booster for all americans 16 and over? >> actually, jake, i'm rather surprised because i would have thought that the committee would look at the safety data and the immunogenicity data. and i think those data are clear, and they would...

To get under the veil of protection of a vaccine. right now, we, at the nih, the companies are all doing studies to do what we call age deescalation. looking at 11 to 9, 9 to 6, 6 to 2. and then, six months to two years, we're collecting safety data and we're collecting immunogenicity data. we're going to have enough data where the companies will be able to present the data to the cdc by the mid-fall or so. somewhere around september or octob october for pfizer. a little bit later for moderna. the fda then has the task, which they did so well now with the bla, of looking at the data and making...

Appropriately is what about 11 down to 5 and even lower, namely the elementary school kids who everyone really wants to get under the veil of protection of a vaccine. right now we at the nih, the companies are all doing studies to do what we all age de-escalation, looking at 11 to 9, 9 to 6, 6 to 2, and then 6 months to 2 years. we're collecting safety data and we're collecting immunogenicity data. we'll have enough data to present to the cdc by mid-fall or so, september, october, for pfizer. a little later for moderna. the fda has the task, which they did so bell now with the bla of looking a...

Representative image ANI | Updated: Feb 24, 2021 22:15 IST New Delhi [India], February 24 (ANI): The Central Drugs Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC) has recommended additional immunogenicity data from Dr Reddy's Laboratories which applied to the national drugs regulator seeking emergency use approval for Sputnik V, a Russian COVID-19 Vaccine. "Today, SEC meeting helped discuss the application of Dr Reddy seeking emergency use approval for Sputnik V vaccine. However, the pharma company has been asked to submit additio...